CTX-10726 — Initial data
Q4
The first patients in the Phase 1 study for CTX-10726 (PD-1 x VEGF-A bispecific antibody) have been dosed and the study is actively enrolling, with initial data expected in Q4.Source filing
CMPX biotech catalysts & pipeline
COMPASS THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
CTX-8371 — Initial data
Q4 2026
Additional data from the cohort expansions are expected in Q4 2026.Source filing
tovecimig — NDA/BLA submission
Q4 26
Q4 26: Submit BLASource filing